UMOD-ulating CKD risk: untangling the relationship between urinary uromodulin, blood pressure, and kidney disease by Turner, MP, Staplin, N

Kidney disease trials for the 21st century: innovations in design and conduct by Herrington, W, Staplin, N, Haynes, R

Allocated but not treated: the silent 16% – Authors' reply by Horby, P, Staplin, N, Emberson, J, Haynes, R, Landray, M

Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease by Zhu, D, Staplin, N, Haynes, R, Herrington, W, Judge, P

Mortality risks in different subtypes of masked hypertension in the Spanish ambulatory blood pressure monitoring registry by de la Sierra, A, Ruilope, LM, Staplin, N, Stergiou, GS, Williams, B

Evidence for the prevention and treatment of stroke in dialysis patients by Herrington, W, Haynes, R, Staplin, N, Emberson, J, Baigent, C, Landray, M

The impact of social disadvantage in moderate-to-severe chronic kidney disease: an equity-focused systematic review. by Morton, R, Schlackow, I, Mihaylova, B, Staplin, N, Gray, A, Cass, A

Fibroblast growth factor-23 and risk of cardiovascular diseases: a Mendelian randomization study by Donovan, K, Herrington, W, Haynes, R, Sardell, R, Baigent, C, Holmes, M, Staplin, N

The authors reply by Chapman, D, Judge, PK, Arnold, T, Staplin, N, Clark, S, Haynes, R, Moffat, S, Herrington, WG, Hill, M

Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis by Shankar-Hari, M, Vale, CL, Godolphin, PJ, Haynes, R, Horby, PW, Landray, MJ, Staplin, N

Conventional and genetic evidence on the association between adiposity and chronic kidney disease by Zhu, P, Herrington, W, Haynes, R, Emberson, J, Landray, M, Baigent, C, Lewington, S, Staplin, N

Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD by Lamprea-Montealegre, J, Staplin, N, Herrington, W, Haynes, R, Emberson, J, Baigent, C, al., E

Mixed‐effects models for slope‐based endpoints in clinical trials of chronic kidney disease by Vonesh, E, Tighiouart, H, Ying, J, Heerspink, HL, Lewis, J, Staplin, N, Inker, L, Greene, T

Use of causal diagrams to inform the analysis and interpretation of observational studies: An example from the Study of Heart and Renal Protection (SHARP) by Staplin, N, Herrington, W, Judge, P, Reith, C, Haynes, R, Landray, M, Baigent, C, Emberson, J

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank by Zhu, P, Lewington, S, Haynes, R, Emberson, J, Landray, M, Woodward, M, Baigent, C, Herrington, W, Staplin, N

A blunted nocturnal blood pressure decline is associated with all-cause and cardiovascular mortality by de la Sierra, A, Staplin, N, Ruilope, LM, Gorostidi, M, Vinyoles, E, Segura, J, Baigent, C, Williams, B

Use of gel-based separator tubes to stabilise phosphate in mailed blood samples. by Herrington, W, Clark, S, Staplin, N, Kumar, A, Illingworth, N, Sutherland, S, Baigent, C, Landray, M, Haynes, R, Hill, M

Methylprednisolone, intravenous immunoglobulin, tocilizimab or anakinra for children with Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS CoV-2 (PIMS-T... by Haynes, R, Landray, M, Staplin, N, Spata, E, Peto, L, Knight, M, Mafham, M, Emberson, J, Horby, P

Conventional and genetic evidence on the association between adiposity and CKD by Zhu, P, Herrington, WG, Haynes, R, Emberson, J, Landray, MJ, Sudlow, CLM, Woodward, M, Baigent, C, Lewington, S, Staplin, N

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial by Haynes, R, Blackwell, L, Staplin, N, Herrington, W, Emberson, J, Judge, P, Storey, B, Landray, M, Baigent, C, Friend, P